Poxel S.A. (EPA:POXEL)

France flag France · Delayed Price · Currency is EUR
0.3870
-0.0025 (-0.64%)
May 6, 2025, 3:09 PM CET
-40.00%
Market Cap 20.90M
Revenue (ttm) 2.19M
Net Income (ttm) -16.11M
Shares Out 53.67M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 59,611
Average Volume 1,424,876
Open 0.3920
Previous Close 0.3895
Day's Range 0.3830 - 0.3920
52-Week Range 0.1150 - 0.7470
Beta 1.84
RSI 52.67
Earnings Date Apr 22, 2025

About Poxel

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatoh... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 6
Stock Exchange Euronext Paris
Ticker Symbol POXEL
Full Company Profile

Financial Performance

In 2023, Poxel's revenue was 1.98 million, an increase of 193.92% compared to the previous year's 674,000. Losses were -35.09 million, 11.8% more than in 2022.

Financial Statements

News

Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wit...

6 weeks ago - Business Wire

Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wit...

3 months ago - Business Wire

Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wit...

6 months ago - Business Wire

Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges

Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges

7 months ago - GuruFocus

Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with...

7 months ago - Business Wire

Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wit...

7 months ago - Business Wire

Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with...

8 months ago - Business Wire

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan

OSAKA, Japan & LYON, France--(BUSINESS WIRE)--Regulatory News: Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) and POXEL SA (Euronext : P...

9 months ago - Business Wire

Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wit...

10 months ago - Business Wire

Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with...

1 year ago - Business Wire

Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious...

1 year ago - Business Wire

Poxel to Report Its 2023 Annual Results by the End of April 2024

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with...

1 year ago - Business Wire